| Diabetes Mellitus, Non-Insulin-Dependent

Cycloset vs Mounjaro

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.

Deep comparison between: Cycloset vs Mounjaro with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsMounjaro has a higher rate of injection site reactions vs Cycloset based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Mounjaro but not Cycloset, including UnitedHealthcare

Category

Cycloset

Mounjaro

At A Glance

RouteOral

FrequencyDaily

ClassDopamine D2 receptor agonist

RouteSC injection

FrequencyOnce weekly

ClassGIP/GLP-1 receptor agonist

Indications

Diabetes Mellitus, Non-Insulin-Dependent

Diabetes Mellitus, Non-Insulin-Dependent

Dosing

Diabetes Mellitus, Non-Insulin-Dependent 1.6 mg to 4.8 mg once daily within 2 hours after waking in the morning with food; initiate at 0.8 mg, increase by one tablet per week to maximal tolerated dose; limit to 1.6 mg daily with moderate CYP3A4 inhibitors; avoid with strong CYP3A4 inhibitors.

Diabetes Mellitus, Non-Insulin-Dependent Start at 2.5 mg SC once weekly; increase to 5 mg after 4 weeks; escalate in 2.5 mg increments every >=4 weeks as needed; max 15 mg once weekly in adults and 10 mg once weekly in pediatric patients 10 years of age and older.

Contraindications

Known hypersensitivity to bromocriptine, ergot-related drugs, or any excipient in CYCLOSET
Syncopal migraine
Postpartum patients
Lactating patients

Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Known serious hypersensitivity to tirzepatide or any excipient in MOUNJARO

Drug Interactions

1193View drug interactions

299View drug interactions

Adverse Reactions

Most common (>=5%) Nausea, fatigue, vomiting, headache, dizziness, rhinitis, constipation, sinusitis, diarrhea, asthenia, somnolence, dyspepsia, amblyopia, anorexia

Serious Hypotension, psychotic disorders, somnolence, syncope, fibrotic-related complications, cardiovascular events (myocardial infarction, stroke)

Postmarketing Hallucinations, retroperitoneal fibrosis, pulmonary fibrosis, pleural effusion, pericarditis, pericardial effusions, cardiac valvulopathy, psychotic and psychiatric disorders, impulse control/compulsive behaviors, neuroleptic-like malignant syndrome

Most common (>=5%) Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain

Serious Risk of thyroid C-cell tumors, acute pancreatitis, hypoglycemia (with insulin secretagogues or insulin), hypersensitivity reactions, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, diabetic retinopathy complications, acute gallbladder disease, pulmonary aspiration

Postmarketing Anaphylaxis, angioedema, acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation including fecal impaction, pulmonary aspiration, acute renal failure or worsening of chronic renal failure, alopecia

Pharmacology

CYCLOSET (bromocriptine mesylate) is a sympatholytic dopamine D2 receptor agonist; timed morning administration in type 2 diabetes is associated with increased insulin sensitivity and glucose disposal and reduced fasting and postprandial hyperglycemia without raising plasma insulin levels.

Tirzepatide is a dual GIP and GLP-1 receptor agonist that selectively binds and activates both receptors, enhancing first- and second-phase insulin secretion and reducing glucagon levels in a glucose-dependent manner, thereby lowering fasting and postprandial glucose, decreasing food intake, and reducing body weight.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Cycloset